Novartis: Pruritus trials

The registry lists 17 Pruritus studies with Novartis as lead sponsor. 2 are open to participants now and 14 have results posted.

Phase 2 4Phase 3 11Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingNCT07811869Phase 3
• A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingNCT07700056Phase 3
• Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- AntihistaminesTerminatedNCT05024058Phase 3Results posted
• A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis PatientsTerminatedNCT03948334Phase 2Results posted
• Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque PsoriasisCompletedNCT03668613Phase 3Results posted
• Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to UstekinumabCompletedNCT03553823Phase 2Results posted
• A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic DermatitisTerminatedNCT03517566Phase 2Results posted
• Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT03504852Phase 3Results posted
• Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromeCompletedNCT03440736Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT03066609Phase 3Results posted
• A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.CompletedNCT02752776Phase 4Results posted
• Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe PsoriasisCompletedNCT02595970Phase 3Results posted
• Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type PsoriasisCompletedNCT02474069Phase 3Results posted
• OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) PatientsCompletedNCT02161562Phase 3Results posted
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar PsoriasisCompletedNCT01806597Phase 3Results posted
• Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)CompletedNCT01636687Phase 3Results posted
• Safety and Efficacy of DNK333 in Atopic Dermatitis PatientsCompletedNCT01033097Phase 2